(Q38555243)

4 September 2017

1 reference

title

Physiological and pathophysiological roles of NAMPT and NAD metabolism (English)

1 reference

4 September 2017

1 reference

6

Wieland Kiess

1 reference

4 September 2017

Antje Garten

1

1 reference

4 September 2017

Susanne Schuster

2

1 reference

4 September 2017

Melanie Penke

3

1 reference

4 September 2017

Theresa Gorski

4

1 reference

4 September 2017

Tommaso de Giorgis

5

1 reference

4 September 2017

language of work or name

1 reference

28 July 2015

1 reference

Nature Reviews Endocrinology

4 September 2017

published in

1 reference

4 September 2017

volume

11

1 reference

4 September 2017

issue

9

1 reference

4 September 2017

page(s)

535-546

1 reference

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nampt: linking NAD biology, metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Crystallization of human nicotinamide phosphoribosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

NAD⁺ metabolism: a therapeutic target for age-related metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

NAD biosynthesis in humans--enzymes, metabolites and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

SIRT1 and other sirtuins in metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Poly(ADP-ribose): PARadigms and PARadoxes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

A role of intracellular mono-ADP-ribosylation in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Expression and regulation of nampt in human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD(+) biosynthetic machinery in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The release of the adipocytokine visfatin is regulated by glucose and insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Ox-LDL induces ER stress and promotes the adipokines secretion in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Blockade of visfatin induction by oleanolic acid via disturbing IL-6-TRAF6-NF-κB signaling of adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin/Nampt: an adipokine with cardiovascular impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin: a new player in mesangial cell physiology and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin regulates genes related to lipid metabolism in porcine adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Shift work or food intake during the rest phase promotes metabolic disruption and desynchrony of liver genes in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin levels in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Increasing NAD synthesis in muscle via nicotinamide phosphoribosyltransferase is not sufficient to promote oxidative metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Mechanism linking diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Role of adipocytokines in predicting the development of diabetes and its late complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Adipokines - removing road blocks to obesity and diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Medicine. Visfatin: a new adipokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

NAD+ and sirtuins in aging and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Inflamm-aging. An evolutionary perspective on immunosenescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The NAD metabolome--a key determinant of cancer cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Anticancer agent CHS-828 inhibits cellular synthesis of NAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

APO866 activity in hematologic malignancies: a preclinical in vitro study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Association of adipokines with obesity in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Serum visfatin levels, adiposity and glucose metabolism in obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin in juvenile obesity - the effect of obesity intervention and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Body fat distribution has no effect on serum visfatin levels in healthy female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Skeletal muscle NAMPT is induced by exercise in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Increased levels and adipose tissue expression of visfatin in morbidly obese women: the relationship with pro-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

TNF-alpha alters visfatin and adiponectin levels in human fat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Central visfatin causes orexigenic effects in chicks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Serum visfatin increases with progressive beta-cell deterioration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Insulin-like effects of visfatin on human osteoblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Extension of human cell lifespan by nicotinamide phosphoribosyltransferase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin/Nampt induces telomere damage and senescence in human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population - results from the PolSenior substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin, a potential biomarker and prognostic factor for endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.117

On respiratory impairment in cancer cells

31 March 2020

1 reference

12 December 2020

Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls.

1 reference

12 December 2020

The management of nicotinamide and nicotinic acid in the mouse

1 reference

12 December 2020

Adipose tissue and adipokines: the association with and application of adipokines in obesity

1 reference

12 December 2020

Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity

1 reference

12 December 2020

An evaluation of visfatin levels in obese subjects.

1 reference

12 December 2020

Elevated visfatin levels in obese children are related to proinflammatory factors

1 reference

12 December 2020

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis

1 reference

12 December 2020

Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery

1 reference

12 December 2020

Visceral adipose tissue visfatin in nonalcoholic fatty liver disease

1 reference

12 December 2020

Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging

1 reference

12 December 2020

Purification and characterization of poly (ADP-ribose) synthetase from human placenta

1 reference

12 December 2020

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil

1 reference

12 December 2020

Enzymatic synthesis of nicotinamide mononucleotide.

1 reference

12 December 2020

Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.

1 reference

12 December 2020

Serum visfatin levels in a group of Egyptian obese individuals

1 reference

12 December 2020

Effects of visfatin/PBEF/NAMPT on feeding behaviour and hypothalamic neuromodulators in the rat.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2015.117

1 reference

4 September 2017

1 reference